Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ABX 1100

Next Previous
Drug Profile

ABX 1100

Alternative Names: ABX-1100

Latest Information Update: 25 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen
  • Developer Aro Biotherapeutics
  • Class Centyrin drug conjugates; Centyrins; Small interfering RNA
  • Mechanism of Action Glycogen synthase expression inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glycogen storage disease type II
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Glycogen storage disease type II

Most Recent Events

  • 11 Feb 2025 Aro Biotherapeutics completes a phase I clinical trials in Glycogen storage disease type II (In volunteers) in Canada (Parenteral) (NCT06109948)
  • 05 Feb 2025 US FDA approves IND application for ABX 1100 in Glycogen storage disease type II
  • 05 Feb 2025 Efficacy, pharmacokinetics and adverse event data from a phase I trial in Glycogen storage disease type II released by Aro Biotherapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top